Skip to content
Biodatica
Start free

Genmab

Tucson, Arizona

OncologyantibodyPhase IIIListed · GMAB

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

1w agoTrial registeredJul 8, 2026Source filing (opens the source filing in a new tab)

Momentum

92no change

Momentum 92 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Aug 13, 2024

    Diffuse Large B-Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Genmab · A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    ClinicalTrials.gov · NCT06508658 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Feb 5, 2024

    Follicular Lymphoma (FL) · RECRUITING · sponsor: Genmab · Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

    ClinicalTrials.gov · NCT06191744 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Feb 8, 2023

    Diffuse Large B-Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Genmab · A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    ClinicalTrials.gov · NCT05578976 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Oct 4, 2022

    Non-hodgkin Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Genmab · Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

    ClinicalTrials.gov · NCT05206357 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Sep 20, 2022

    Follicular Lymphoma (FL) · ACTIVE_NOT_RECRUITING · sponsor: Genmab · Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

    ClinicalTrials.gov · NCT05409066 (opens the source filing in a new tab)

  6. Trial

    PHASE2 registered

    Aug 17, 2022

    Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Genmab · A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

    ClinicalTrials.gov · NCT05451810 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Jun 14, 2022

    Non-Hodgkin Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Genmab · A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

    ClinicalTrials.gov · NCT05283720 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources